丹芪鳖甲软肝颗粒联合恩替卡韦治疗慢性乙型肝炎肝纤维化疗效观察

Observation on the curative effect of Danqi Biejia Ruangan Granule combined with entecavir in treatment of chronic hepatitis B patients with liver fibrosis

目的观察丹芪鳖甲软肝颗粒联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法将100例慢性乙型肝炎患者随机分为观察组和对照组,对照组采用恩替卡韦治疗,观察组在上述治疗基础上加用丹芪鳖甲软肝颗粒治疗,比较2组临床疗效及治疗前后肝功能指标、肝纤维化指标、B超指标及不良反应发生情况。结果观察组总有效率明显高于对照组(P<0.05);观察组治疗后肝功能指标(ALT、AST、TBil、ALB)、肝纤维化指标(HA、LN、PC-Ⅲ、Ⅳ-C)及B超指标(门静脉主干内径和脾脏厚度)均较治疗前明显改善(P均<0.05),且观察组治疗后ALT、AST、TBIL、HA、LN、PC-Ⅲ、Ⅳ-C、门静脉主干内径和脾脏厚度均明显低于对照组,ALB高于对照组,差异均有统计学意义(P均<0.05);2组均未出现严重不良反应,不良反应发生率比较差异无统计学意义(P>0.05)。结论丹芪鳖甲软肝颗粒联合恩替卡韦治疗慢性乙型肝炎肝纤维化有助于改善患者肝功能,延缓肝纤维化,疗效显著,可在临床上推广。

Objective It is to observe the curative effect of Danqi Biejia Ruangan Granule （DBRG） combined entecavir in treatment of chronic hepatitis B patients with hepatic fibrosis. Methods 100 cases of patients with chronic hepatitis B were ran- domly divided into the observation group and the control group, the patients were treated with entecavir in control group and enteeavir combined with DBRG in the observation group. The clinical curative effect, and the indexes of liver function, liver fibrosis markers, ultrasound index and adverse reactions before and after treatment were observed and compared between the two groups. Results The total effective rate of observation group was significantly higher than that of control group （P 〈 0.05）. After treatment, the liver function （ALT, AST, TBil, ALB） , hepatic fibrosis index （ HA, LN, PC - lff , 1V - C） and ultrasound index （portal vein trunk diameter, thickness of spleen） of the observation group were significantly improved than before treatment （ all P 〈 0.05） , and the ALT, AST, TBil, HA, LN, PC - 111 , IV - C, portal vein diameter and thick- ness of spleen of the observation group were significantly lower but ALB was significantly higher than those of the control group （ all P 〈 0.05 ）. There was no serious adverse reactions in two groups, and was no significant difference in adverse reaction in- cidence rate （ all P 〉 0.05）. Conclusion DBRG combined with entecavir in treatment of chronic hepatitis B patients with liver fibrosis is helpful to improve the liver function of patients, delay hepatic fibrosis, and with significant effect, so it can be pop- ularized in clinic.